

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 18th February 2026 10-12.30pm

Microsoft Teams Meeting

	Present	
	Veronica Rainey (Chair) Victoria Gemmell (Prof Sec) Kirsty Macfarlane Lynn Duff (for TS) David Semple Craig Thurtell Rachael Kelly Kaven Stafford Penny Brankin Quorate (minimum 6 members) – Y	Stephanie Dundas Graeme Bryson Christine Carswell Chris Miller Lucy Munro (until item 5) Colin Angus (from item 5 onwards) Eimear Gordon (from Item 6) Invited Attendees: Lesley Walker (Item 8b)
1.	Apologies for Absence	
	Kelly Ballie, Gail Richardson, Alistair Brown, Saurabh Kumar,	
2.	Declaration of Interest	
	Nil	
3.	Ratification of minutes of January 2026 meeting	
	Approved	
4.	Matters arising not covered elsewhere on the agenda	
	<p>a. R-hGH Guideline – Ian Hunter Further discussions ongoing with GP Subcommittee. Final feedback awaited.</p> <p>b. Vabysmo (Faricimab) – Umaima Mulla Update awaited.</p> <p>c. Warfarin Protocol – Christine Paterson Update awaited.</p> <p>d. Lithium – Lorna Templeton Update awaited.</p> <p>e. Procainamide for Tachyarrhythmias SBAR – Penny Brankin PB gave an update on discussions at the Resus Committee. This will be taken forward.</p> <p>f. Homebirth Guideline – Gordon Buchanan Update awaited.</p> <p>g. Stroke Guideline (Guideline for genetic testing for cyp2c19 gene for patients with incident transient ischaemic attack or acute ischaemic stroke in NHS Lanarkshire) – Sarah Brady/Dr Mark Barber This was approved.</p> <p>h. Progesterone – Gordon Buchanan Update awaited.</p> <p>i. Forensic mental health inpatients accessing and using private providers for healthcare – David Semple DS gave feedback. There was discussion around the need for consistency and the</p>	

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 18th February 2026 10-12.30pm

Microsoft Teams Meeting

	<p>difficulties around the number of variables in each individual situation. A suggestion was made to include a section in Patient’s Own Medicines section of the Code of Practice, which is currently undergoing review. A view from the Mental Health Welfare Commission will be shared with further discussions to take this forward.</p> <p>j. Co-codamol Shortage – Kirsty MacFarlane KM presented finalised documents. There has been extensive consultation on these and a request was made for 3 months expiry, with ongoing situation monitoring. This was approved.</p> <p>k. Intravenous Acetazolamide Guideline – Ruth Waters Queries were raised around patient consent and chain of contact. These will be fed back to the author. This was not approved at this time.</p> <p>l. Osteoporosis – Zhou Min Chong Updates were required to this guideline as the service is now using biosimilars which are out with SMC remit, and so references to different medicines approval routes had to be revised, including IPTRs. This was approved.</p>	
5.	ADTC Committee Business	
	Nil	
6.	SMC Advice (CONFIDENTIAL)	RK
6.1	a. SMC Advice – February 2026 RK outlined actions post-ADTC for new SMC advice which was agreed.	
6.2	Updates to NHS LK status on SMC advice RK outlined proposed updates in designations for SMC medicines. This was agreed.	
6.3	Updates to Lanarkshire Bulletins These were agreed.	
6.4	Outstanding SMC New Medicines Decisions Nil	
7.	Lanarkshire Formulary / West of Scotland Formulary	KM
7.1	<p>NHSLK formulary changes proposals RK presented proposed formulary amendments which were approved. This included updates to listings of discontinued and out of stock products, and addition of notification banners to the formulary BNF chapters which are now being discussed as part of the West Regional Formulary. Updates to the Prescribing Notes for Isotretinoin following the updated MHRA drug safety update was agreed. A small amendment denoting the off-label dosing of Proxor at certain doses was agreed.</p> <p>Gluten Free Food Formulary RK outlined the proposed minor changes to the Lanarkshire Gluten Free Food Formulary, including updating the listed name of certain products and also removing discontinued products. This was approved.</p>	
7.2	West of Scotland Formulary Updates VG gave an update on progress. Skin and Cardiovascular chapters were presented for	

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 18th February 2026 10-12.30pm

Microsoft Teams Meeting

	<p>comments from the committee. Chapter Summary documents were presented and noted. Details on the membership of the Regional Committee and NHSL representation were described and agreement given that this would be an acceptable delegated committee for formulary approval. A helpful comparison document has been created by the RF team. This was well received and committee members fed back positively. An SBAR was presented and discussed regarding the inclusion of Epimax cream to the RF. There are conflicting opinions on inclusion of this. NHSL ADTC committee was satisfied with the safety of the product, and the measures planned by the Regional Team to increase awareness of appropriate useage and agreed Epimax can be included as an option.</p>	
BREAK (10 MINUTES)		
8.	Clinical Protocols & Guidelines	
	<p>a. Paediatric Diabetes Mellitus Chart for Daily Subcutaneous Insulin Dose Prescription – Lynsay McAulay An number of comments were received which will be fed back to the author. This was approved, pending clarifications.</p> <p>b. Application for Xonvea addition to NHS Lanarkshire formulary SBAR – Lesley Walker * LW gave an overview. It was noted that this medicine has been rejected by SMC on both clinical and economic grounds. SMC notes that there was uncertainty that use would lead to any significant reduction in hospitalisation. There was also a query around the licensing, which notes limited evidence for hyperemesis gravidarum. Potential options to permit access were discussed and it was agreed that the current option of PACS2 process remains the most appropriate route.</p>	
9.	ULM Requests	
	<p>a. Clonidine ULM – Jennifer Murphy The committee agreed to approved the request due to the urgent nature, subject to some clarifications, and with a 12 month expiry.</p> <p>b. Asthma Guideline ULM – Leo Haddock This was approved.</p> <p>c. Denosumab ULM – Linda Johnstone This was approved.</p>	
10.	New Medicine Safety Notifications & Alerts	MM
	<p>a. CAS - Home https://www.gov.uk/drug-safety-update</p> <p>i. <u>GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases</u> noted-no action</p> <p>ii. <u>Isotretinoin – changes to prescribing guidance and additional risk minimisation measures</u> noted-formulary webpage updated</p> <p>b. MHRA Safety Roundup – January 2026 Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs</p>	

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 18th February 2026 10-12.30pm

Microsoft Teams Meeting

	Noted-no action c. NatPSA NATIONAL PATIENT SAFETY ALERT/2026/002/MHRA – CLASS 1 MEDICINES RECALL – QUETIAPINE ORAL SUSPENSION ALL STRENGTHS (UNLICENSED MEDICINE) MANUFACTURED BY EASTSTONE LIMITED GRB reassured the committee that actions under the alert were completed.	
11.	Prescribing Management Board Update	GRB
	PMMB is updating their ToR to align more closely with ADTC, including quality and safety elements. There are also plans to bring in some additional governance around Hosted Services.	
12.	Medicines for the Treatment of Cancer	KB
	Nil	
13.	Medicines Code of Practice	
	Nil	
14.	PGD Activity Report	RK
	RK outlined the updates to the Lanarkshire PGD Database in the month of January. Of the recently approved updated ED PGDs, RK highlighted to the committee that a number of these have been given a shortened expiry date, in order for teams to explore supply of some of these medicines via a protocol. RK also highlighted PGDs expiring in the month of March, and GRB outlined the board governance procedure for notifying authors and specialities of the expiring PGDs.	
15.	Antimicrobial Management Team Update	SD
	a. Update on Indicators and Antibiotic Use ** SD described the updated indicators. There will be actions for both Primary and Secondary Care. NHSL Antimicrobial Team will take these forward. b. Amikacin guideline – Claire McDonald This was approved.	
16.	Lay member related items	
	A question was asked about the National shortage of co-codamol. VR explained the current situation and plans for mitigation.	
17.	Correspondence	
	Nil	
18.	AOCB	
	Nil	
19.	Date of Next Meeting	
	Wednesday 18 th March 2026 10am-12.30pm MS TEAMS	